Professor Ahmed Elzawawy, is the president of ICEDOC’s Experts in Cancer Without Borders, USA, President elect of The African Organization for Research and Training in Cancer (AORTIC), Co-President of The South and East Mediterranean College of Oncology (SEMCO) and Coordinator of The Win-Win Initiative that aims at the increase of the affordability of better value cancer treatment in the world via scientific approaches.
Locally In Egypt, Ahmed Elzawawy is a Professor and founder of The Clinical Oncology dept., Suez Canal University and Chairman of clinical and Radiation Oncology Centre, Al Soliman Hospital, Port Said, Egypt.
Calum Kerr MBA, BSc has driven structural and cultural change as a National Health Service Redesign Manager and Head of Corporate Affairs for many years in a national context. Calum is a qualified Coach and Mediator.
David contributes to Oxford as Professor of Cancer Medicine, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital.
He has an international reputation for the treatment of, and research into, colorectal cancer and the quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation.
David has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement; Chair of the National Cancer Services Collaborative, instigator of the Department of Health’s networked approach to clinical cancer research and developed a 20 year plan for the future of the NHS in Scotland, the "Kerr Report".
He was elected Fellow of the Academy of Medical Sciences in 2000, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 and was elected President of the European Society of Medical Oncology in 2010.
Stewart Kerr is a project manager for a small charity trying to reduce the burden of cancer in Africa, the Africa Oxford Cancer Foundation (AfrOx - www.afrox.org). He has a degree in Emergency and Disaster Management from Coventry University.
Through his work for AfrOx Stewart has experience in all areas of the project cycle, designing, managing, monitoring, evaluating, communicating with stakeholders and disseminating results among stakeholders.
Peter Naredi is professor of surgery and head of the department of surgery, Sahlgrenska academy and Sahlgrenska university hospital in Gothenburg, Sweden.
He has extensive experience in clinical and experimental cancer research and has performed global phase III studies. Peter has experience in implementing a national cancer plan on the regional level, with eg telemedicine MDT boards, centralization of specialized cancer diagnostics and surgery, education and research programmes.
Donna O’Brien, President of Strategic Visions in Healthcare (NY), has a consulting practice in healthcare strategy, policy, and operations and expertise in cancer program planning and implementation. She is frequently engaged by CEOs and Boards for large transformation projects and driving innovation.
She has held Executive positions in academic medical centers and health systems including MD Anderson Cancer Center and has served on the Boards of several national hospital systems in the US.
In 2009 she received the US National Institutes of Health Director’s Award for her work on the team that developed and implemented the 30 hospital National Cancer Institute Community Cancer Centers Program (NCCCP).
Dr Prendergast, a former Rhodes Scholar, is currently the Emeritus Director for the Mayo Clinic Center for Individual Medicine at the Mayo Clinic and is the Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology at the Mayo Medical School.
Formerly, Dr Prendergast was the Director of the Mayo Clinic Comprehensive Cancer Center; a Presidential Appointee to the National Cancer Advisory Board/National Institutes of Health; and he was the Chair of Research of the Mayo Foundation. He is a member of the Board of Directors of the Eli Lilly Company.
Currently Head of Dept of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIMS), New Delhi since 2007. He has been on the faculty of this premier Institute of India since 1990.
For the last 15 years he has been conducting 3 year fellowship courses of DM in Medical Oncology and has trained about 60 residents. Many of these consultants are now in various parts of India and also abroad.
His main interests are focused on clinical trials, breast cancer, lung cancer, lymphomas and leukemias, high dose chemotherapy and transplants. He has led more than 50 local and international research projects, including various drug trials, and carried out more than 200 high dose chemotherapy and stem cell transplants in various cancers.
Vinod has authored more than 160 publications on various aspects of cancer in peer reviewed national and international journals.
He was head of the National Cancer Center in Muscat, Oman from Nov 2001– Feb 2004 and was also the co-founder of the INDOX Cancer Research Network.
Eva Segelov is a senior Medical Oncologist at St Vincent’s Hospital, Sydney Australia and Associate Professor of Medicine at the University of New South Wales. She is a recognised national and international expert in the fields of breast and gastrointestinal cancer. Research interests relate to translational studies of targeted therapies in defined subpopulations to increase benefit and reduce toxicity of cancer treatments. She is the Principal Investigator on a number of international and national academic clinical trials and is a sought after speaker in the Asia-Pacific region.
Dr Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology.
His research focuses on Phase I and II studies with pharmacodynamic endpoints with novel agents directed to membrane receptors, such as the EGFR-family and IGF-1R, and the PI3K and ERK signalling pathways, as well as downstream cytoplasmic and intranucleur effectors like Mdm2/p53 and aurora kinase. One of the main objectives of the group is also to identify new predictive markers of response to treatments and markers of primary (de novo) resistance and secondary treatment.